Global Duchenne Muscular Dystrophy Market Size Study, by Therapeutic Area (Molecular-Based Therapies, Steroid Therapy), by Distribution Channel (Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies), and Regional Forecasts 2022-2032

Global Duchenne Muscular Dystrophy Market Size Study, by Therapeutic Area (Molecular-Based Therapies, Steroid Therapy), by Distribution Channel (Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies), and Regional Forecasts 2022-2032

The global Duchenne muscular dystrophy (DMD) market is valued approximately at USD 1.38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.7% over the forecast period 2024-2032. DMD is a genetic disorder marked by progressive muscle degeneration and weakness due to alterations in the dystrophin protein. Predominantly affecting males, the disease manifests in early childhood with symptoms such as delayed motor development and difficulties in learning to talk. The progressive nature of the disease leads to significant skeletal and cardiac muscle atrophy, necessitating comprehensive management strategies including glucocorticoid therapy and physical therapy to delay the onset of severe complications.

Current treatments focus on managing symptoms and improving quality of life. The development of exon skipping therapies, driven by significant advances in genetic research, has provided new avenues for market growth. The introduction of these therapies by key market players is expected to drive the market forward. Moreover, the increasing incidence of DMD and the active pipeline of novel drugs further bolster market expansion. However, the high cost associated with DMD treatments poses a significant barrier to market growth. Despite this, the rising demand for advanced healthcare services and the substantial investments in healthcare infrastructure, especially in emerging economies, present lucrative opportunities for market players. Governments' increased spending on the pharmaceutical and biotechnology sectors in developing countries is expected to further propel market growth.

The key region in the Global Duchenne Muscular Dystrophy Market include North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America accounted for the majority of the global market share in 2021 and is expected to maintain its dominance due to technological advancements and a robust hospital infrastructure. The Asia-Pacific region is projected to grow at the highest CAGR, fueled by rising DMD cases, healthcare infrastructure development, and increased investment in healthcare projects.


By Therapeutic Area

Molecular-Based Therapies

Steroid Therapy

By Distribution Channel

Hospital Pharmacies

Drug Store & Retail Pharmacies

Online Pharmacies

Key Market Players:

Hoffmann-La Roche AG

FibroGen, Inc

GlaxoSmithKline plc

Italfarmaco S.p.A.

Nippon Shinyaku Co., Ltd

Pfizer Inc.

PTC Therapeutics

Santhera Pharmaceuticals Inc

Sarepta Therapeutics

Wave Life Sciences Ltd.

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.